Recent advances in the development of mutant-selective EGFR inhibitors for non-small cell lung cancer patients with EGFR-TKI resistance

Ítems similars

• Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor—resistant non-small cell lung cancer
  per: Jiang, Tao, et al.
  Publicat: (2014)
• Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer
  per: Ge, Liangqing, et al.
  Publicat: (2015)
• Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
  per: Kwon, Byoung Soo, et al.
  Publicat: (2017)
• Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell lung cancer: a propensity-matched retrospective study
  per: Wang, Xia, et al.
  Publicat: (2021)
• Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance
  per: Han, Ruoshuang, et al.
  Publicat: (2021)